Yahoo Finance Singapore report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
Why TFX Stock slipped -1.15% Today — RQD Quant Desk Flash
Teleflex Incorporated (TFX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Teleflex Incorporated (NYSE: TFX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $139.77 (-1.15% 1D, market cap $5.99B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TFX ranks #318 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TFX compare to MMSI and STVN in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), TFX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 56.2%, and ROIC of 1.8%. By comparison, MMSI (Merit Medical Systems Inc.) holds a B grade (75/100 RQD, P/E 43.4x, ROIC 7.8%, cap $5.58B) and STVN (Stevanato Group S.p.A.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $5.53B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TFX?
▼
Per TFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000096943), Teleflex Incorporated generated $1.99B in revenue (+17.2% YoY), -$905.6M in net income, and $0 in free cash flow against $6.95B in total assets and $2.54B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.6% realized swing band)
FRED Regime × Technicals: 88% of 52W Range • RSI-14 at 70.2 (OVERBOUGHT (>70))
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a TFX Turnaround Squeeze
While TFX currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($131.45) and Max Pain ($146.76) forces dealer call-delta covering toward $157.51.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why TFX Stock slipped -1.15% Today — RQD Quant Desk Flash
Teleflex Incorporated (TFX) slipped -1.15% to $139.77, trading at 88% of its 52-week range ($100.18 – $145). Stretched risk/reward at current multiples (2% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 88% of its 52-week range ($100.18 – $145) with RSI-14 at 70.2 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.6% around $139.77 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 56.2% gross margin and $30.0M annual free cash flow.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
Teleflex reported that the U.S. FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for PCI, recognizing its potential to address unmet clinical needs in treating serious coronary d
WAYNE, Pa., October 22, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designa
WAYNE, Pa., October 22, 2026--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TFX)
- ✓Walkthrough of TFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
TFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TFX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TFX. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TFX)
1. Head-to-Head Health Care Peer Comparison (TFX vs. MMSI, STVN, HAE, MMED)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Teleflex Incorporated (TFX) ranks #318 by composite RQD confidence (48/100, grade D) and #147 by equity capitalization ($5.99B). Within this direct 5-issuer industry benchmark cohort, MMSI leads on earnings valuation at 43.4x trailing P/E, while HAE leads on capital efficiency and profitability with 8.4% ROIC and 59.0% gross margin. MMSI currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with TFX at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TFX
ACTIVE
Teleflex Incorporated | D | 48/100 | — | 56.2% | 1.8% | -1.15% | $5.99B | Benchmark Subject |
| MMSI Merit Medical Systems Inc. | B | 75/100 | 43.4x | 48.7% | 7.8% | -7.66% | $5.58B | /mmsi-vs-tfx → |
| STVN Stevanato Group S.p.A. | D+ | 58/100 | — | — | — | -4.25% | $5.53B | /stvn-vs-tfx → |
| HAE Haemonetics Corporation | B | 74/100 | — | 59.0% | 8.4% | -0.12% | $5.45B | /hae-vs-tfx → |
| MMED MiniMed Group Inc. | D | 46/100 | — | 54.2% | -3.9% | -5.04% | $5.42B | /mmed-vs-tfx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000096943In its most recent audited fiscal period (FY2025, filed 2025-12-31), Teleflex Incorporated (TFX) reported GAAP revenue of $1.99B (+17.2% vs. FY2024 revenue of $1.70B , and +16.4% cumulative change since FY2023) , GAAP net income of -$905.6M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, TFX closed FY2025 with $6.95B in total assets against $2.54B in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.99B | -$905.6M | — | — | $6.95B | $2.54B |
| FY2024 (FY) | 2024-12-31 | $1.70B | $70.2M | — | — | $7.10B | $1.56B |
| FY2023 (FY) | 2023-12-31 | $1.71B | $357.6M | — | — | $3.30B | $771.0M |
3. TFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Teleflex Incorporated (NYSE: TFX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $139.77 (-1.15% 1D, market cap $5.99B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TFX ranks #318 in composite RQD confidence.
How does TFX compare to MMSI and STVN in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), TFX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 56.2%, and ROIC of 1.8%. By comparison, MMSI (Merit Medical Systems Inc.) holds a B grade (75/100 RQD, P/E 43.4x, ROIC 7.8%, cap $5.58B) and STVN (Stevanato Group S.p.A.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $5.53B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TFX?
Per TFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000096943), Teleflex Incorporated generated $1.99B in revenue (+17.2% YoY), -$905.6M in net income, and $0 in free cash flow against $6.95B in total assets and $2.54B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TFX trading relative to its 50-day, 200-day, and 52-week technical levels?
TFX last traded at $139.77 (-1.15% on volume of 891,302 shares), positioning the stock +6.33% above its 50-day simple moving average ($131.45) and +11.34% above its 200-day simple moving average ($125.54). Across its 52-week range of $100.18 to $145.00, TFX sits at the 88.3% percentile with a 14-day RSI of 70.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.6% ($131.94 to $147.60).
TFX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TFX stock moving today?
Why TFX Stock slipped -1.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (2% return on capital) under elevated 10-year interest-rate pressure.
TFX — Teleflex Incorporated: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, TFX scores 48 out of 100, a grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 6 out of 20, reflecting ROIC of 1.8% and an FCF yield of -18%; this is the weakest pillar and indicates the business is not currently generating attractive returns on invested capital or positive free cash flow. The Whale 13F Flow pillar scores 17 out of 20, the strongest pillar, reflecting institutional accumulation and options positioning. Insider Conviction scores 5 out of 20, reflecting SEC Form 4 and Congressional PTR cluster flow that the rating characterizes as weak. Macro Regime Fit scores 11 out of 20, with a Beta of 0.98 and a sector sensitivity profile. Forensic Balance Sheet scores 9 out of 20, reflecting an Altman Z of 2.12, a Piotroski F of 4 out of 9, and Debt/Equity of 0.81.
For a prospective investor, the upside case rests mainly on the institutional positioning signal, which is the only pillar near the top of its range. The valuation tradeoff is significant: per the market data, forward P/E is 27 and EV/EBITDA is 40.9 against trailing EPS of -21.37, so the price embeds expectations that the reported cash-generation weakness must reverse. The rating's overall framing is a distribution warning rather than an accumulation signal, meaning the weak fundamental and insider pillars outweigh the institutional flow reading. This is an analytical summary of the source data, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $1992.7M | $118.4M | $-905.6M | N/A | N/A | $378.6M | $2541.4M |
| FY 2024 (filed 2024-12-31) | $1699.5M | $103.7M | $70.2M | N/A | N/A | $247.9M | $1555.9M |
| FY 2023 (filed 2023-12-31) | $1712.4M | $258.7M | $357.6M | N/A | N/A | N/A | $771.0M |
Per the SEC financials, revenue rose from $1712.4M in FY 2023 to $1992.7M in FY 2025, while net income moved from $357.6M to $-905.6M over the same span. Per the market data, operating margin is 5.9% and net margin is -45.4%, and ROIC is 1.8%. Per the Roarable RQD rating, the Altman Z-Score is 2.12, the Piotroski F-Score is 4 out of 9, and Debt/Equity is 0.81. Debt rose from $771.0M in FY 2023 to $2541.4M in FY 2025 per the SEC financials.
Recent Catalysts & News Wire Analysis
The news wire contains six items, each labeled YELLOW with impact label MARKET WIRE. The headlines reference a MarketBeat "Moderate Buy" rating by Wall Street brokerages, a Yahoo Finance forecast item, a research-oriented MarketBeat item, a Yahoo Finance Singapore overview, a price-action item reporting TFX ticking up 0.80% to $129.24 with a negative gamma reference, and a report that State of Alaska Department of Revenue sold TFX shares. The price-action item's summary field contains an unrelated domain reference rather than analysis, and the source label is also a non-financial domain, so its reliability is limited. No proprietary signals are present in the Butterfly graph. Risk watch items per the financials include the net loss in FY 2025 and the rise in debt.
Open Questions
- What is the composition of the FY 2025 net loss of $-905.6M, and does the source data identify any one-time items?
- What is FCF and EPS for any reported period, given that both are N/A in every financials row?
- What products and customers generate the $1992.7M of FY 2025 revenue?
- What is the trailing P/E, given the market data reports it as unavailable while EPS is negative?
- Who holds the institutional and insider positions behind the 17/20 Whale 13F Flow pillar?
TFX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Teleflex Incorporated (TFX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Teleflex Incorporated (TFX) market action, institutional positioning, and fundamental catalysts.
Teleflex reported that the U.S. FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for PCI, recognizing its potential to address unmet clinical needs in treating serious coronary d
TFX Bull vs. Bear Conversation Board — What's Your Call at $139.77?
🔥 Official Bull vs. Bear Debate: Is TFX (D • RQD 48/100) a Buy at $141.39?
Welcome to the TFX (Teleflex Incorporated) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on TFX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on TFX, but look at what you are paying: current EV/EBITDA multiples with 56.2% gross margins. Unless Teleflex Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TFX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on TFX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $141.39 (52-wk range $100.18 - $145.00), any beat on forward guidance forces shorts and underweight funds to chase.